{
  "docId": "019de075-a698-70b1-b3ba-29e176396a9c",
  "docSlug": "63ec8e773c9b43e7b033b64167026114",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 32,
  "pageCount": 52,
  "prevPage": 31,
  "nextPage": 33,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "Includes a scientific mechanism of action diagram showing iMX-110 effects on tumor microenvironment.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/32",
  "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c",
  "deckJsonHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c.json",
  "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-32",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.76,
        "x": 0.12,
        "y": 0.585
      },
      "kind": "callout",
      "text": "Scientific Basis: IMX-110 turns “cold” tumors “hot” in genetic (KPC) mouse models of pancreatic cancer",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5ee940fd-4ed8-47c2-9b91-d388690128b9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.72
      },
      "kind": "diagram",
      "text": "Mechanism of action flow: eliminating T-regs -> enabling T-lymphocytes -> eliminating vascularization",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5bd7e10e-2f06-401a-b01e-cf32cbc1907e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.1,
        "y": 0.15
      },
      "kind": "image",
      "text": "BeiGene, ImmixBio, Novartis logos",
      "attrs": null,
      "subkind": "logo-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9d9ac2e7-6fa2-41e5-a347-f60c6df6477c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.68,
        "y": 0.35
      },
      "kind": "list",
      "text": "Joint Alliance Committee: Members from ImmixBio & BeiGene will coordinate.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5eeda942-3c79-42bd-b4aa-a29edcb33ea4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.35,
        "y": 0.35
      },
      "kind": "list",
      "text": "Combination Trial Design: iMX-110 + tislelizumab; 30 patient Phase 1b study.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6b9129a3-e228-41b5-9798-6788fbc55669",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.02,
        "y": 0.35
      },
      "kind": "list",
      "text": "Study Goal: Demonstrate potential for TSTx in combination therapies; Rapid expansion into oncology indications.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ff2f148d-c786-4142-b2c6-d919ed9fe27b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.88
      },
      "kind": "paragraph",
      "text": "As of June 2021, in China, tislelizumab has already been approved or granted conditional approved in 5 cancer indications.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ed83b5bb-acbd-46ca-9f73-03098a79183a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "Clinical Trial and Supply Agreement with BeiGene for Tislelizumab (Anti-PD-1 mAb)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "35250662-9932-4c7b-89af-211378fa6198",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "causal-chain",
      "slug": null,
      "matchId": "bf0bcc4d-c62b-4b13-a290-21cbc5698a14",
      "evidence": "Mechanism of action diagram showing sequential biological effects",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}